These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24726088)

  • 21. Teneligliptin: a review in type 2 diabetes.
    Scott LJ
    Clin Drug Investig; 2015 Nov; 35(11):765-72. PubMed ID: 26475720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib.
    Derks M; Fowler S; Kuhlmann O
    Clin Ther; 2009 Mar; 31(3):586-99. PubMed ID: 19393849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
    Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
    Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Yamada Y
    Adv Ther; 2020 May; 37(5):2477-2492. PubMed ID: 32323194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor - Teneligliptin in rats using liquid chromatography-tandem mass spectrometry.
    Shantikumar S; Satheeshkumar N; Srinivas R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Oct; 1002():194-200. PubMed ID: 26340762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioequivalence of Linagliptin 5 mg once daily and 2.5 mg twice daily: pharmacokinetics and pharmacodynamics in an open-label crossover trial.
    Friedrich C; Jungnik A; Retlich S; Ring A; Meinicke T
    Drug Res (Stuttg); 2014 May; 64(5):269-75. PubMed ID: 24154935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Teneligliptin for the treatment of type 2 diabetes.
    Goda M; Kadowaki T
    Drugs Today (Barc); 2013 Oct; 49(10):615-29. PubMed ID: 24191255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: Evaluation by continuous glucose monitoring.
    Wada N; Mori K; Nakagawa C; Sawa J; Kumeda Y; Shoji T; Emoto M; Inaba M
    J Diabetes Complications; 2015; 29(8):1310-3. PubMed ID: 26298521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.
    Kim TE; Lim KS; Park MK; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Sep; 34(9):1986-98. PubMed ID: 22943970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
    Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
    Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Matsukawa M; Yamada Y
    Adv Ther; 2020 Mar; 37(3):1065-1086. PubMed ID: 31873865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: a randomized non-inferior test.
    Kamiko K; Aoki K; Kamiyama H; Taguri M; Shibata E; Ashiya Y; Minagawa F; Shinoda K; Nakajima S; Terauchi Y
    J Clin Pharmacol; 2015 Feb; 55(2):144-51. PubMed ID: 25159300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients.
    Salem AH; Yang J; Graham A; Patnaik A; Holen K; Pradhan R; Xiong H
    Anticancer Res; 2014 Apr; 34(4):2001-6. PubMed ID: 24692738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects.
    Luedtke D; Marzin K; Jungnik A; von Wangenheim U; Dallinger C
    Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):533-541. PubMed ID: 29500603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients.
    Li J; Klemm K; O'Farrell AM; Guler HP; Cherrington JM; Schwartz S; Boyea T
    Curr Med Res Opin; 2010 Aug; 26(8):2003-10. PubMed ID: 20583949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.
    Stroh M; Palcza J; McCrea J; Marsilio S; Breidinger S; Panebianco D; Johnson-Levonas A; Kraft WK; Orford K; Murphy G; Agrawal N; Trucksis M; Wagner JA; Iwamoto M
    Cancer Chemother Pharmacol; 2012 May; 69(5):1247-53. PubMed ID: 22290273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects.
    Chen L; Boinpally R; Gad N; Greenberg WM; Wangsa J; Periclou A; Ghahramani P
    Clin Drug Investig; 2015 Oct; 35(10):601-12. PubMed ID: 26315684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanistic insights from sequential combination therapy with a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin.
    Okahata S; Sakamoto K; Mitsumatsu T; Kondo Y; Tanaka S; Shiba T
    Diabetes Obes Metab; 2019 Feb; 21(2):388-392. PubMed ID: 30146790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
    Fukuda-Tsuru S; Anabuki J; Abe Y; Yoshida K; Ishii S
    Eur J Pharmacol; 2012 Dec; 696(1-3):194-202. PubMed ID: 23022337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.